ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0196

Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI)

Zoe Reed1, Xana Howard1, Cristina Arriens1, Teresa Aberle1, Wade DeJager2, Joan Merrill3 and Judith James1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

Meeting: ACR Convergence 2024

Keywords: Cohort Study, Epidemiology, race/ethnicity, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Healthcare Disparities in Rheumatology Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that disproportionately affects young women of certain racial and ethnic minority groups with enhanced severity and early mortality. Adverse social determinants of health also negatively impact SLE outcomes, which may confound some associations of disease severity with race and ethnicity. However, in many clinical settings and historical cohorts, measures of social determinants of health are missing or incomplete. This exploratory study assessed whether the Center for Disease Control’s Social Vulnerability Index (SVI) is a potential contributing factor to the higher prevalence and severity of SLE among some underserved groups.  

Methods: Female patients from the Oklahoma Cohort of Rheumatic Disease (OCRD), a longitudinal cohort of unique patients who meet ACR, SLICC, and ACR/EULAR classification criteria for SLE, were used in this analysis (n=516). A Lupus Severity Index (LSI) was determined by the Montgomery method (Bello et al. Lupus Science Medicine 2016). The SVI for 2020 was categorized into four groups as defined by the CDC: Rank 1 (least vulnerable) to Rank 4 (most vulnerable). Descriptive statistics were computed for OCRD SLE female patients by SVI rank and race, focusing on White and Black SLE patients due to small sample sizes in the other racial groups. OCRD White and Black female patients were compared to Oklahoma’s average female population based on 2020 Census Bureau data.

Results: Among the OCRD patients, the LSI and distribution of ACR criteria did not differ based on SVI rank (Table 1). However, the LSI was significantly higher in Black patients compared to White patients (p=0.0092), and a higher percentage of Black patients were classified as Rank 4 on the SVI (p=0.0059; Table 2). ACR criteria also differed based on race, with a higher percentage of Black patients experiencing discoid rash, serositis, renal, and hematologic manifestations and a lower percentage of Black patients experiencing malar rash (Table 2). In addition, the distribution of SVI ranks significantly differed in Black OCRD patients compared to the average Black female Oklahoma population (Figure 1; p< 0.0001). Notably, a higher percentage of OCRD patients were classified as Rank 1 compared to the general population, with a similar percentage also classified as Rank 4. The distribution of SVI rank in White patients was similar in both populations (Figure 1).

Conclusion: In the OCRD, Black female patients experienced more severe disease, and a higher percentage was classified as socially vulnerable compared to White female patients, suggesting that adverse social determinants of health may contribute to increased severity in this population. Even though referral patterns to the cohort include uninsured, underinsured, and insured patients, significant differences in the SVI ranks were identified between Black OCRD patients and the Black female Oklahoma population, perhaps influenced in part by increased indigenous admixture in cohort referral patterns.

Supporting image 1

Table 1: Demographic Table for OCRD Female SLE patients by Social Vulnerability Index

Supporting image 2

Table 2: Demographic Table for OCRD Female SLE Patients by Race

Supporting image 3

Figure 1: Comparison of the Social Vulnerability Index (SVI) among OCRD Female SLE patients and the Oklahoma Female Population by Race and Ethnicity


Disclosures: Z. Reed: None; X. Howard: None; C. Arriens: AstraZeneca, 1, 5, 6, Aurinia, 1, 6, Bristol-Myers Squibb(BMS), 1, 5, Cabaletta, 1, GlaxoSmithKlein(GSK), 1, Kezar, 1, Synthekine, 1, UCB, 1; T. Aberle: None; W. DeJager: None; J. Merrill: AbbVie, 1, 2, Alexion, 1, 2, Alumis, 1, 2, Amgen, 1, 2, AstraZeneca, 1, 2, 5, Aurinia, 1, 2, Bristol Myers Squibb, 1, 2, 5, EMD Serono, 1, 2, Genentech, 1, 2, Gilead, 1, 2, GlaxoSmithKline, 1, 2, 5, Kezar, 1, 2, Lilly, 1, 2, Merck, 1, 2, Pfizer, 1, 2, Provention, 1, 2, Remegen, 1, 2, Sanofi, 1, 2, Takeda, 1, 2, UCB, 1, 2, Zenas, 1, 2; J. James: GlaxoSmithKlein(GSK), 1, Progentec Diagnostics, Inc., 5, 10.

To cite this abstract in AMA style:

Reed Z, Howard X, Arriens C, Aberle T, DeJager W, Merrill J, James J. Associations Between Systemic Lupus Erythematosus (SLE) and the Social Vulnerability Index (SVI) [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/associations-between-systemic-lupus-erythematosus-sle-and-the-social-vulnerability-index-svi/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-between-systemic-lupus-erythematosus-sle-and-the-social-vulnerability-index-svi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology